164 related articles for article (PubMed ID: 27126611)
1. N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.
Jennings GK; Ritchie CM; Shock LS; Lyons CE; Hackett JC
Mol Pharmacol; 2016 Jul; 90(1):42-51. PubMed ID: 27126611
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.
Guengerich FP; McCarty KD; Chapman JG
J Biol Chem; 2021; 296():100223. PubMed ID: 33449875
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
Sevrioukova IF; Poulos TL
Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
[TBL] [Abstract][Full Text] [Related]
4. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
Sevrioukova IF; Poulos TL
J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
[TBL] [Abstract][Full Text] [Related]
5. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
Samuels ER; Sevrioukova IF
Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
Samuels ER; Sevrioukova I
Biochemistry; 2019 Apr; 58(15):2077-2087. PubMed ID: 30912932
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
[TBL] [Abstract][Full Text] [Related]
8. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.
Sevrioukova IF; Poulos TL
Biochemistry; 2013 Jul; 52(26):4474-81. PubMed ID: 23746300
[TBL] [Abstract][Full Text] [Related]
9. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
Sevrioukova IF; Poulos TL
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
[TBL] [Abstract][Full Text] [Related]
11. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
Lee JY; Kang NS; Kang YK
Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
[TBL] [Abstract][Full Text] [Related]
12. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.
Hsu MH; Savas U; Johnson EF
Mol Pharmacol; 2018 Jan; 93(1):14-24. PubMed ID: 29093019
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
[TBL] [Abstract][Full Text] [Related]
14. Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.
Samuels ER; Sevrioukova IF
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806297
[TBL] [Abstract][Full Text] [Related]
15. Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules.
Sevrioukova I
Biochemistry; 2019 Feb; 58(7):930-939. PubMed ID: 30676743
[TBL] [Abstract][Full Text] [Related]
16. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Loos NHC; Beijnen JH; Schinkel AH
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
[TBL] [Abstract][Full Text] [Related]
17. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
Nembri S; Grisoni F; Consonni V; Todeschini R
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
[TBL] [Abstract][Full Text] [Related]
19. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
Wright WC; Chenge J; Wang J; Girvan HM; Yang L; Chai SC; Huber AD; Wu J; Oladimeji PO; Munro AW; Chen T
J Med Chem; 2020 Feb; 63(3):1415-1433. PubMed ID: 31965799
[TBL] [Abstract][Full Text] [Related]
20. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4.
Hsu MH; Johnson EF
J Biol Chem; 2019 May; 294(20):8015-8022. PubMed ID: 30926609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
